Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses the shift in toxicity profiles of cancer therapies from traditional chemotherapy to targeted agents, noting similar overall toxicities but with different side effects, and reports no new findings.

In this cross-sectional study, researchers found no significant difference in effectiveness between paclitaxel-carboplatin and pemetrexed-carboplatin for treating pulmonary adenocarcinoma with negative EGFR mutations, but paclitaxel-carboplatin was more cost-effective and associated with more frequent severe haematological toxicities.

This article reviews methotrexate's pharmacokinetics and toxicity, emphasizing the role of urinary excretion and leucovorin in avoiding most toxic reactions; it provides no new clinical results.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

This study mapped the safety profile of EGFR-TKIs by analyzing FDA adverse event reports, highlighting unexpected reactions like intestinal obstruction and hypokalaemia with gefitinib and erlotinib.

This review describes the unique pharmacological profile and clinical applications of pegylated liposomal doxorubicin, emphasizing its role in Kaposi's sarcoma and recurrent ovarian cancer, but reports no new clinical results.

This review outlines dermatological toxicities associated with targeted cancer therapies and immunotherapies, emphasizing the need for collaborative management by oncologists and dermatologists but reports no new clinical findings.

This review discusses the role of mTOR kinase in pulmonary fibrosis and explores how mTOR inhibitors may help slow the progression of this condition, but it reports no new results.

This report presents the Taiwanese Dermatological Association's 2016 consensus on defining and managing skin toxicities from EGFR-TKI treatments, providing comprehensive guidelines for clinicians in Taiwan.

This review discusses various treatment challenges and toxicities in patients with relapsed follicular lymphoma and suggests that novel therapies could improve outcomes by reducing exposure to harmful chemotherapy cycles.

In this case study, researchers reported on a 54-year-old woman who developed methotrexate toxicity after mistakenly taking high doses over five days, which led to mucocutaneous lesions and pancytopenia, highlighting the importance of early recognition and treatment of such toxicities.

In this review, researchers explored the complex mechanisms behind chemotherapy-induced side effects like nausea, fatigue, and hair loss, and discussed potential strategies using natural agents to manage these toxicities, improving understanding for targeted adjunct therapies.

This article discusses multiple minute digitate hyperkeratosis in a dermatological context and reports no new clinical findings; the authors focus on a descriptive review.

This case report describes the first instance of ANCA positive vasculitis secondary to Mycobacterium abscessus pulmonary disease, highlighting the complex interplay of immune dysfunction and treatment challenges.

This review highlights that chemotherapy-induced skin toxicities from EGFR inhibitors in breast cancer treatment can significantly impact patient quality of life and treatment adherence, emphasizing the importance of proactive management and patient discussions.

In this systematic review, animal studies showed that cytarabine causes multi-organ toxicities, notably neurotoxicity, linked to oxidative stress and other mechanisms, though study quality raises concerns about reliability and translation to human outcomes.

This study highlights that prolonged voriconazole use is linked to an increased risk of aggressive cutaneous malignancies like squamous cell carcinoma, necessitating careful monitoring of drug levels to manage adverse effects.

This review discusses the pharmacology, toxicology, and clinical efficacy of flavonoids and saponins, highlighting the need for more data on their pharmacokinetics, interactions, and toxicities as most research is still in vitro.

This study described the safety profile of tyrosine kinase inhibitors in treating various solid tumors, finding that the observed toxicities were consistent with existing literature.

This review discusses supplements used to alleviate side effects of chemotherapy, highlighting various natural remedies, but reports no original clinical research findings.

This guideline outlines the management of systemic lupus erythematosus in adults but reports no new clinical findings.

Azathioprine's effectiveness and safety require careful monitoring and more research, especially regarding its use with corticosteroids and the role of TPMT status in patients.

This phase II study found that gemcitabine plus paclitaxel showed promising activity and manageable toxicity as first-line therapy for recurrent or metastatic breast cancer, with a 35% overall response rate.

This review examines the role of topoisomerase-interacting drugs in cancer treatment and emphasizes the importance of understanding their mechanisms for clinical development, but it presents no new results.

This review discusses current strategies for head and neck cancer treatment, highlighting the effectiveness of cisplatin in combination therapies, and notes increased toxicity with multimodal treatments but no overall survival advantage for doublet regimens; it reports no new clinical results.

This article discusses the factors influencing anticancer therapeutic regimens and reviews mechanisms of action and side effects of major chemotherapeutic agents without reporting new research findings.

This symposium reviewed strategies to advance stalled drug molecules, discussed common regulatory hurdles, and explored options for repurposing drugs, but it reported no new research findings.

The conference presented findings on how vitamin D levels, genetic factors, and lifestyle choices like smoking and yoga affect various health conditions and diseases.